datalabs-logo

  • Ask Datalabs
  • My Feed
  • Companies
  • Investors
  • People
  • Funding Rounds
  • Acquisitions

  • Research Reports
  • Industries
  • Locations
Orbicular Pharmaceutical Technologies-logo
Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies-logoOrbicular Pharmaceutical Technologies-logo
Orbicular Pharmaceutical Technologies

Orbicular Pharmaceutical Technologies - Financials, Revenue, P&L Statement, Balance Sheet, Cash Flow & More

Private
Orbicular Pharmaceutical Technologies Private Limited
Private
Orbicular Pharmaceutical Technologies Private Limited
2010
2010

Founded in 2010, Orbicular Pharmaceutical Technologies operates in Health Tech offering specialty pharmaceutical solutions through the development of niche and complex dosage forms for licensing to gl...

Funding stage:

Undisclosed

Last funding:

30/05/2024

Total funding:

$20.00 Mn+

Revenue:

₹182.7 Cr+ (FY24)
Prev. FY

Investors

Employee count:

260

Last 90d

260

Last 90d

Web traffic:

469

469

Last 30d

Last 30d

Glassdoor Rating:

Orbicular Pharmaceutical Technologies: Financial Breakdown

Decoding financial health metrics of Orbicular Pharmaceutical Technologies

  • total_revenue_logo
    Total Revenue
    ₹182.7 Cr
    6%

    Prev. FY

  • total_expenses_logo
    Total Expenses
    ₹118.8 Cr
    39%

    Prev. FY

  • profit_after_tax_logo
    Profit After Tax
    ₹26.0 Cr
    -55%

    Prev. FY

  • total_assets_logo
    Total Assets
    ₹539.5 Cr
    40%

    Prev. FY

  • net_profit_margin_logo
    Net Profit Margin
    0.1%
    -58%

    Prev. FY

Note: Above mentioned stats are for FY23-24

FAQs on Financials of Orbicular Pharmaceutical Technologies

Yes. In FY24, Orbicular Pharmaceutical Technologies reported a profit after tax of ₹26.0 Cr, making it profitable.

Orbicular Pharmaceutical Technologies's revenue grew 6.2% year-on-year, from ₹172.1 Cr in FY23 to ₹182.7 Cr in FY24.

Orbicular Pharmaceutical Technologies's estimated EBITDA for FY24 was ₹82.8 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.

In FY24, Orbicular Pharmaceutical Technologies posted revenue of ₹182.7 Cr (up 6.2% YoY) and a profit after tax of ₹26.0 Cr. Explore the full financials of Orbicular Pharmaceutical Technologies here...

Disclaimer

Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.

Quick Links

MY FEEDDISCOVERRESEARCH